The expression of EGFR is 20–50‐fold higher in solid tumors, including breast cancer, compared to that found in normal tissues.[10] Moreover, EGFR is overexpressed in more than 50% of TNBC patients, which is markedly higher than that for other subtypes of breast cancer [56] and is significantly correlated with poor prognosis.[57] Therefore, drug treatments targeting EGFR, including inhibitors of EGFR (TKIs) and mAbs, have been developed over the last two decades. The gene discussed is EGFR; the disease is breast cancer.